Review Article
Volume 5 Issue 8 - 2022
Coronavirus Disease; Long COVID: Global War Against a Novel Virus
Gundu HR Rao*
Emeritus Professor, Laboratory Medicine and Pathology. Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA
*Corresponding Author: Gundu HR Rao, Emeritus Professor, Laboratory Medicine and Pathology. Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA.
Received: June 24, 2022; Published: July 27, 2022




Abstract

Current coronavirus pandemic is unprecedented and the global response to a great extent, has demonstrated how unprepared we were, despite the past experiences of earlier ‘flu’ pandemics. Now we are in the third year of the pandemic, with the fifth COVID surge rising in many countries. The pandemic started, with the emergence of Alpha variant from Wuhan, China and has continued to evolve into more and more transmissible variants, Beta, Delta and currently, Omicron. We warned you but you did not listen, says a report titled “A World at Risk” published in September 2019, by the Global Preparedness Monitoring Board (GPMB). When the new coronavirus was identified in Wuhan, China, the virus’s entire genetic makeup, or ‘genome’ was published online within days. Advances in gene sequencing has allowed scientists, to trace and monitor the spread of the virus worldwide and the evolving nature of newer variants. The viral outbreak was followed by immediate surge of academic publications, in less than five months more than 15,000 publications appeared and exceeded 80,000 by the end of 2020. The media reported every milestone, in the spread of the virus worldwide, as well as about the vaccines and drug development activities. Unfortunately, the spread of false and misleading information by some sources, drowned credible information. The magnitude of development that has taken place and the speed with which mRNA vaccines and antiviral drugs were developed during this crisis, is historical and remarkable. Pharmaceutical companies achieved “things we never thought could be done”, to combat the pandemic quickly. In just over a year, due to the biggest vaccination campaign in history, more than 12 billion doses of vaccines have been administered across 184 countries. On a global scale, 73 countries have given at least one dose, to 75% of the population. With 2.8 billion people worldwide, still not vaccinated against COVID-19, the health experts worry that we are prematurely moving away from the pandemic. We are at war with a killer virus, which has caused unprecedented economic crisis. Some people who have been infected with the coronavirus, have reported their experience of long-term effects and lingering COVID-19 symptoms, known as post COVID conditions (PCC), or long COVID, or as the experts refer, post-acute sequelae of SARS-CoV-2 (PASC). We have not seen the end of COVID-19 epidemic, as we still have new surges of this virus in various geographical regions of the world. In a large study of 47,780 patients discharged following COVID-19, almost a third were admitted again to the hospitals and a similar proportion were diagnosed with respiratory diseases, according to studies published in the Lancet and British Medical Journal (BMJ). The National Health Services of UK officially launched a long COVID service, to support recovery in October of 2020. Post COVID Care Centers (PCCC) are opening across the country, bringing together multidisciplinary teams, across a broad range of specialties. Long Covid Services in Europe is highlighted by the 6.6-billion pounds funding it has received. The World Health Organization (WHO) has urged member countries, to prioritize rehabilitation for the medium and long-term consequences of COVID-19 and to gather information on “long Covid: more systematically. The COVID-19 pandemic was caused by $16 trillion virus and the cost of long COVID is estimated at $2.6 trillion. These numbers are nothing but estimates. No one knows, the true economic burden of such diseases.

Keywords: COVID-19; SARS-CoV-2; Novel Virus

References

  1. Taubenberger JK and Morens DM. “1918 Influenza: the Mother of All Pandemics”. Emerging Infectious Diseases1 (2006): 15-22.
  2. Lederberg J. “Infectious History”. Science5464 (2003): 287.
  3. Lederberg J. “Man versus microbe: warfare at its worst”. Nature Reviews Microbiology1 (2014): 1.
  4. “Covid-19: First coronavirus was described in The BMJ in 1965”. BMJ 369 (2020): m1547.
  5. Hu B., et al. “Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of coronaviruses”. PLoS Pathology (2017).
  6. Latinne A., et al. Origin and cross-species transmission of bat coronaviruses in China (2020).
  7. Zhu Na., et al. “A Novel Coronavirus from Patients with Pneumonia in China, 2019”. The New England Journal of Medicine8 (2020): 727-733.
  8. Cui J., et al. “Origin and evolution of pathogenic coronaviruses”. Nature Reviews Microbiology 17 (2019): 181-192.
  9. Guo Y., et al. “The origin, transmission, and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status”. Military Medical Research11 (2020).
  10. Lu R., et al. “Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet10224 (2020): 565-574.
  11. Maxmen A. “Scientists struggle to probe COVID’s origins amid sparse data from China”. Nature 603 (2022): 773-775.
  12. Sigler T., et al. “The socio-spatial determinants of COVID-19 diffusion: the impact of globalization, settlement characteristics and population”. Globalization and Health 56 (2021).
  13. Magesh S., et al. “Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status. A systematic review and meta-analysis”. JAMA Network Open11 (2021): e2134147.
  14. Bhaskaran K., et al. “Population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform”. Lancet 6 (2021): 100109.
  15. Rao GHR. “COVID-19 and Cardiometabolic Diseases.: Guest Editorial”. EC Cardiology6 (2020): 08-12.
  16. Rao GHR. “Coronavirus Disease (COVID-19) and Acute Vascular Events: Editorial”. Clinical and Applied Thrombosis/Hemostasis (2020): 26.
  17. Rao GHR. “Coronavirus (COVID-19), Comorbidities, and Acute Vascular Events; Guest Editorial”. ECCMC EC Clinical Case Reports6 (2020): 87-91.
  18. Rao GHR. “Coronavirus Disease (Covid-19), Comorbidities, and Clinical Manifestations. Guest Editorial”. EC Diabetes and Metabolic Research6 (2020): 27-33.
  19. Rao GHR. “Coronavirus Disease (Covid-19): A Disease of the Vascular Endothelium”. Series of Cardiology Research1 (2020): 23-27.
  20. Rao GHR. “Covid-19: A Public Health Perspective”. Journal of Medicine and Healthcare4 (2020): 1-7.
  21. Rao GHR. “Coronavirus Transmission, Vascular Dysfunction and Pathology”. Journal of Cardiology Research Review and Reports 3 (2020): 1-4.
  22. Rao GHR. “SARS-CoV-2 biochemistry, Transmission, Clinical Manifestations and Prevention”. International Journal of Biomedicine4 (2020): 303-311.
  23. Rao GHR. “Clinical manifestation of coronavirus disease as it relates to cardio-vascular health”. Frontiers in Cardiovascular Medicine1 (2020): 20-103.
  24. Rao GHR. “Syndemic of Coronavirus Disease and Metabolic Diseases: Global Perspective”. EC Endocrinology and Metabolic Research4 (2021): 28-32.
  25. Rao GHR. The Tsunami of a Killer Virus (SARS-CoV-2) Ravages India: Call for Action (2021).
  26. Rao GHR. “Twindemic of Coronavirus Disease and Cardiometabolic Diseases”. BioMed Research International2 (2021): 111-122.
  27. Rao GHR. “Biomedicine in the COVID Age: Opportunities, Responses, and Challenges”. International Journal of Biomedical Research3 (2021): 241-249.
  28. Rao GHR. “Coronavirus Disease: An Additional Risk Factor for Acute Vascular Events”. Diabetes and Obesity International Journal4 (2021): 000250.
  29. Rao GHR. “Metabolic Diseases Enhance the Severity of Coronavirus Disease”. Journal of Pathology and Infectious Diseases1 (2021): 1-8.
  30. Rao GHR. “Coronavirus Disease (SARS-CoV-2) and Vascular Dysfunction. Point of View”. EC Clinical and Med EC Clinical and Medical Case Reports Case Reports.2 (2022).
  31. Ahirwar R., et al. “Biochemical composition, transmission, and diagnosis of SARS-CoV-2”. Bioscience Reports8 (2021): BSR20211238.
  32. Alipoor SD., et al. “COVID-19: Molecular and Cellular Response”. Frontiers in Cellular and Infection Microbiology (2021).
  33. Peacock TP., et al. “The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets”. Nature Microbiology 6 (2021): 899-909.
  34. Mallapaty S. “Where did Omicron come from? Three key theories”. Nature 602 (2022): 26-28.
  35. Stokes EK., et al. “Coronavirus Disease 2019 Case Surveillance-United States, January22-May 30, 2020”. Morbidity and Mortality Weekly Report 69 (2020): 759.
  36. Richardson S., et al. “Presenting characteristics, comorbidities, and outcomes among 5700 hospitalized patients in the New York Area”. The Journal of the American Medical Association20 (2020): 2052.
  37. Clementi N., et al. “Viral respiratory pathogens and lung injury”. Clinical Microbiology Reviews3 (2020): e00103-e00120.
  38. Huertas A., et al. “Endothelial cell dysfunction: a major player in SARS-Cov-2 infection (COVID-19)?” European Respiratory Journal 56 (2020): 2001634.
  39. Charfeddline S., et al. “Long COVID19 Syndrome: Is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study”. Frontiers in Cardiovascular Medicine (2021).
  40. Groff D., et al. “Short-term and Long-term Rates of Postacute Sequalae of SARS-CoV-2 Infection”. JAMA Network Open10 (2021): e2128568.
  41. Chen C., et al. “Global prevalence of Post-Acute Sequalae of COVID-19(PASC) or Long COVID: A Meta-Analysis and Systematic Review”. Med Rxiv (2021).
  42. Augustin M., et al. “Post-COVID syndrome in non-hospitalized patients with COVID-19: a longitudinal prospective cohort study”. The Lancet Regional Health 6 (2021): 100122-100122.
  43. Al-Aly Z., et al. “Long COVID after breakthrough SARS-CoV-2 Infection”. Nature Medicine (2022).
  44. Raman B., et al. “Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, equality of the life and mental health, post-hospital discharge”. Lancet 31 (29021): 100683.
  45. Appleby J. “The Public Cost of Covid-19”. British Medical Journal 376 (2022): o490.
  46. Cutler DM. “The Costs of Long Covid”. The Journal of the American Medical Association5 (2022): e221809.
  47. Huang L., et al. “Health outcomes in people 2 years after surviving hospitalization with COVID-19: a longitudinal study”. Lancet (2022).
  48. Ledford H. “Coronavirus ‘ghosts’ found lingering in the gut”. Nature (2021).
  49. Gaebler C., et al. “Evolution of antibody immunity to SARS-CoV-2”. Nature 591 (2021): 639-644.
  50. Natarajan A., et al. “Gastrointestinal symptoms and fecal shedding of SARS-CoV-2RNA suggest prolonged gastrointestinal infection”. Medicine (2022).
  51. Liu Q., et al. “Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome”. Gut (BMJ Journals3 (2021): 2021.
  52. Ma C., et al. “COVID-19 and the digestive system”. The American Journal of Gastroenterology (2020).
  53. Abbasi J. “The COVID Heart-One Year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks”. The Journal of the American Medical Association 327 (2022): 1113-1114.
  54. Guo P., et al. “COVCOG 1: Factors predicting physical, neurological symptoms in Long COVID in a community sample. A first publication from the COVID and cognition study”. Frontiers in Aging Neuroscience (2022).
  55. Wang X., et al. “Potential effects of coronavirus on the liver: An Update”. Frontiers in Medicine (2021).
  56. Yende S and Parikh CR. “Long COVID and Kidney Disease”. Nature Reviews Nephrology 17 (2021): 792-793.
  57. Evans PC., et al. “Endothelial dysfunction in COVID-19: a position paper of the ESC working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science”. Cardiovascular Research 116 (2020): 2177-2184.
  58. Charfeddine S., et al. “Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with Long-COVID-19: Insights from TUN-EndCOV Study”. Frontiers in Cardiovascular Medicine (2022).
  59. Gayathri Choda and Rao GHR. “Thermal Imaging for Early Diagnosis of Vascular Dysfunction: A Case Report”. Journal of Clinical Cardiology and Diagnostics2 (2019): 1-7.
  60. Rao GHR. “Flow Velocity, Flid dynamics and Vascular Pathophysiology”. Science of the Heart1 (2016): 1-8.
  61. Gandhi P and Rao GHR. “The spectral analysis of photoplethysmography to evaluate an independent cardiovascular risk factor”. International Journal of General Medicine 7 (2014): 539-547.
  62. Celermajer DS., et al. “Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis”. Lancet8828 (1992): 1111-1115.
  63. Su JB. “Vascular endothelial dysfunction and pharmacological treatment”. World Journal of Cardiology11 (2015): 719-741.
  64. Mancini GB., et al. “Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study”. Circulation 94 (1996): 258-265.
  65. Sudano I., et al. “Protection of endothelial function: Targets for nutritional and pharmacological interventions”. Journal of Cardiovascular Pharmacology 47 (2006): S136-S150.
  66. Oduro PK., et al. “Pharmacological management of vascular endothelial dysfunction in diabetes: TCM and western medicine compared based on biomarkers and biochemical parameters”. Pharmacological Research 158 (2020): 104893.
  67. Petitijean SJL., et al. “Multivalent 9-0-Acetylated-sialic acid glycoclusters as potent inhibitors for SARS-CoV-2 infection”. Nature Communications (2022).
  68. Del Rio C and Malani PN. “COVID-19-The beginning of the END or the End of the Beginning?” The Journal of the American Medical Association (2022).
  69. Hoffman C., et al. Covid Reference (2022).
  70. McCorkell L., et al. “Patient-Led Research Collaborative; embedding patients in the Long COVID narrative”. Pain Reports PR 6 (2021): e913.
  71. Prasad P., et al. “The Pandemic Notebook (PDF). A handy guide from THE HINDU on understanding the coronavirus and staying protected against COVID-19” (2020).
Citation: Gundu HR Rao. “Coronavirus Disease; Long COVID: Global War Against a Novel Virus”. EC Clinical and Medical Case Reports 5.8 (2022): 14-28.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 20, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.